Development of CD46 theranostics for imaging and treatment of multiple myeloma
用于多发性骨髓瘤成像和治疗的 CD46 治疗诊断学的开发
基本信息
- 批准号:10539684
- 负责人:
- 金额:$ 67.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAntibody-drug conjugatesAntigensAwardBindingBiodistributionCD46 AntigenCRISPR interferenceCellsCharacteristicsChromosomesClinical TrialsCombined Modality TherapyDataDetectionDevelopmentDiseaseDoseEligibility DeterminationEpitopesGenesGenomicsGoalsHumanImageImmunoglobulin GIsotopesLengthMagnetic Resonance ImagingMalignant NeoplasmsMaximum Tolerated DoseMethodsModelingMolecular TargetMorbidity - disease rateMultiple MyelomaMusPET/CT scanPatient CarePatientsPerformancePhase I Clinical TrialsPhysiciansPilot ProjectsPopulationPositronPositron-Emission TomographyPre-Clinical ModelPreclinical TestingProtocols documentationRadiolabeledRadionuclide therapyRadiopharmaceuticalsRecording of previous eventsRefractoryRelapseScanningSignal TransductionSiteSurfaceTechniquesTestingTherapeuticTherapeutic AgentsTissuesToxic effectXenograft Modelbaseclinical translationcold agglutininsexperiencefluorodeoxyglucosefluorodeoxyglucose positron emission tomographygenome-widehuman modelimaging agentimaging scientistimaging studyimprovedin vivoin vivo evaluationmolecular imagingmortalityneoplastic cellnew therapeutic targetnovelnovel diagnosticsnovel strategiesnovel therapeutic interventionpomalidomidepre-clinicalscreeningstandard of caretargeted agenttargeted treatmenttheranosticstranslational studytreatment strategytumor
项目摘要
PROJECT SUMMARY AND ABSTRACT
The primary goal of this proposal is to develop novel theranostic agents targeting CD46 for imaging and treatment
of multiple myeloma (MM). CD46 is a novel therapeutic target, with a cognate antibody-drug conjugate, FOR46,
now in phase 1 clinical trials. Our preliminary data demonstrate high expression of CD46 in MM. In this proposal,
we develop and implement [89Zr]DFO-YS5 and [225Ac]DOTA-YS5 as imaging and therapeutic agents targeting
MM. The central hypothesis of this proposal is that CD46 is an effective target for molecular imaging and therapy
of MM. In this proposal we test this hypothesis in preclinical models, and in a pilot study of patients with MM.
In order to test this hypothesis, we have assembled an experienced team of chemists, biologists, imaging
scientists, physicists, and physicians to evaluate this method in preclinical models and in patients. In specific aim
1, we will develop [89Zr]DFO-YS5 and [225Ac]DOTA-YS5 as PET imaging and therapeutic agents for MM. In
specific aim 2, we will develop new co-treatment approaches to maximize CD46 expression, and use these to
augment [89Zr]DFO-YS5 PET and [225Ac]DOTA-YS5 treatment. In aim 3, we perform a pilot [89Zr]DFO-YS5 PET
imaging study in patients with MM, and analyze the data to determine its sensitivity for detecting sites of disease.
The methods developed in this proposal will ultimately be used to develop novel diagnostic and therapeutic
approaches in MM, to help reduce morbidity and mortality for this disease.
项目摘要和摘要
这项提议的主要目标是开发以CD46为靶点的新型治疗药物,用于成像和治疗
多发性骨髓瘤(MM)。CD46是一种新的治疗靶点,具有同源抗体-药物结合物FOR46,
目前正在进行第一阶段的临床试验。我们的初步数据显示CD46在MM中高表达。
我们开发并实现了[89Zr]DFO-YS5和[225Ac]DOTA-YS5作为靶向成像和治疗药物
这个提议的中心假设是CD46是分子成像和治疗的有效靶点。
在这项建议中,我们在临床前模型和MM患者的初步研究中检验了这一假设。
为了验证这一假设,我们组建了一个由化学家、生物学家、成像专家组成的经验丰富的团队
科学家、物理学家和内科医生在临床前模型和患者中评估这种方法。以特定的目标
1,我们将开发[89Zr]DFO-YS5和[225Ac]DOTA-YS5作为MM的PET成像和治疗剂。
具体目标2,我们将开发新的共同治疗方法来最大化CD46的表达,并利用这些方法
增加[89Zr]DFO-YS5PET和[225Ac]DOTA-YS5处理。在目标3中,我们进行了中试的[89Zr]DFO-YS5 PET
对多发性骨髓瘤患者进行影像研究,并对数据进行分析,确定其对发现病变部位的敏感性。
本提案中开发的方法最终将用于开发新的诊断和治疗方法
治疗多发性骨髓瘤的方法,以帮助降低这种疾病的发病率和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Richard Flavell其他文献
Robert Richard Flavell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Richard Flavell', 18)}}的其他基金
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy
CD46 定向放射配体治疗的毒性和疗效的系统评价
- 批准号:
10633935 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Development of CD46 theranostics for imaging and treatment of multiple myeloma
用于多发性骨髓瘤成像和治疗的 CD46 治疗诊断学的开发
- 批准号:
10636870 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancer
超极化 13C 间质 pH 成像在前列腺癌风险分层中的应用
- 批准号:
9888209 - 财政年份:2018
- 资助金额:
$ 67.02万 - 项目类别:
相似海外基金
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
- 批准号:
10759731 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Proteasome Inhibitor-Loaded Antibody Drug Conjugates with High Drug Loading For Targeted Treatment of Triple Negative Breast Cancers
负载蛋白酶体抑制剂的高载药量抗体药物偶联物用于三阴性乳腺癌的靶向治疗
- 批准号:
10822628 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Next Generation Bio-Orthogonal Ynamine Reagents for the Preparation of Antibody-Drug Conjugates
用于制备抗体-药物缀合物的下一代生物正交胺试剂
- 批准号:
2889322 - 财政年份:2023
- 资助金额:
$ 67.02万 - 项目类别:
Studentship
Novel antibody-drug conjugates targeting T-cell lymphoma
靶向 T 细胞淋巴瘤的新型抗体-药物偶联物
- 批准号:
10386723 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
Targeting breast cancer via site-specific antibody-drug conjugates based on biosynthetically modified enediyne natural products
通过基于生物合成修饰的烯二炔天然产物的位点特异性抗体药物缀合物靶向乳腺癌
- 批准号:
514898299 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
WBP Fellowship
Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumors
抗恶性皮肤肿瘤抗体药物偶联物生产方法的建立和验证
- 批准号:
22K16283 - 财政年份:2022
- 资助金额:
$ 67.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Developing Novel Bispecific Antibody-Drug Conjugates to Treat Leukaemia
开发新型双特异性抗体药物偶联物来治疗白血病
- 批准号:
2600922 - 财政年份:2021
- 资助金额:
$ 67.02万 - 项目类别:
Studentship
Project 6- Targeting AML using bispecific and antibody drug conjugates
项目 6 - 使用双特异性和抗体药物偶联物靶向 AML
- 批准号:
10615336 - 财政年份:2021
- 资助金额:
$ 67.02万 - 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
- 批准号:
9886056 - 财政年份:2020
- 资助金额:
$ 67.02万 - 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
- 批准号:
10322410 - 财政年份:2020
- 资助金额:
$ 67.02万 - 项目类别: